McClellan Leaves For CMS As Crawford Heads Reorganized FDA
FDA Commissioner Mark McClellan, MD/PhD, is leaving FDA before the agency makes a decision on whether Barr Labs' Plan B (levenorgestrel .75 mg) is approvable for over-the-counter use
FDA Commissioner Mark McClellan, MD/PhD, is leaving FDA before the agency makes a decision on whether Barr Labs' Plan B (levenorgestrel .75 mg) is approvable for over-the-counter use